Keystone Recapitalized by Audax
Concurrently with the sale of its technology and advisory services business, Keystone is spinning out its Core AI business into a newly formed independent entity, Keystone.AI. Keystone.AI is a B2B AI SaaS provider that develops foundation models that assist clients with critical business operations such as demand forecasting, pricing, and inventory planning. Keystone.AI will continue to operate as an independent business with minority ownership by RLH Equity Partners.
RLH Managing Director
Guggenheim Securities, LLC served as lead financial advisor to RLH Equity Partners and Goldman Sachs & Co. LLC served as co-advisor.
About RLH Equity Partners
RLH Equity Partners invests behind passionate entrepreneurs in uniquely positioned, high-growth, knowledge-led B2B enterprises driven by macro changes in technology, healthcare, and regulatory environments. RLH's portfolio companies concentrate on offering specialized consulting, engineering and professional services with $25 million to $150 million of annual revenue at the time of investment. The RLH investment team strives to deliver strategic and operational guidance to its portfolio companies in navigating the opportunities and challenges of scale and rapid growth. RLH's insights and processes to support entrepreneurs in building market leading enterprises have been honed over RLH's more than 40-year history of successful investing. RLH currently manages over $1 billion of assets and is actively seeking new portfolio company investments.
Contact
For more information please contact:
Director of Communications
RLH Equity Partners
949-428-2205
[email protected]
www.rlhequity.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/keystone-recapitalized-by-audax-302662736.html
SOURCE RLH Equity Partners
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Share buybacks in Ericsson during the period August 17 - August 21, 2026
- Daiichi Sankyo Appoints Ken Keller as Chief Commercialization Officer to Lead New Commercialization Unit to Accelerate Growth of Innovative Portfolio
- ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Goldman Sachs, GuggenheimSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share